A Phase 2 interventional study of AND017 capsules and AND017 Placebo in β -Thalassemia, sponsored by Kind Pharmaceuticals LLC. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.
Among the 32 studies in Thalassemia with a site in China, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 5 of the 13 other live ones, and was the 22nd registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:
Rongrong Liu · Sites in China
Ages 18–75
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Sites in China
Ages 3–17
Rongrong Liu · Sites in China
Ages 3–20
Shenzhen Hemogen · Sites in China
Ages 6–35
Shanghai BDgene Co., Ltd. · Sites in China
Ages 3–35
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is above the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 30 across the 27 interventional studies, 30 across the 5 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Kind Pharmaceuticals LLC has 1 study filed under Thalassemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Thalassemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06302491Kind Pharmaceuticals LLCA Study of Safety and Efficiency of AND017 in Patients With β-thalassemia | 2026-12 |
| NCT06465550Shanghai BDgene Co., Ltd.A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major | 2026-12 |
| NCT05851105Shenzhen Hemogenthe Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia | 2026-12-30 |
| NCT07725263Haikou Affiliated Hospital of Central South University Xiangya School of MedicineLow-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children | 2027-02-28 |
| NCT07579949ScinnoHub Pharmaceutical Co., Ltd.A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) | 2027-03-29 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Thalassemia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AND017 capsules
Drug: AND017 capsules
Drug: AND017 capsules
Drug: AND017 Placebo
Administer AND017 capsules once per day (QD)
Administer AND017 matching placebo capsules once per day (QD)
Evaluate the safety and tolerability of different oral doses of AND017 in the treatment of β-thalassemia subjects
Evaluate the safety and tolerability of different oral doses of AND017 in the treatment of β-thalassemia subjects by AE rate by CTCAE 5.0
Time frame: From baseline to Week 24 or End of Treatment if discontinue early
Change in mean Hb levels relative to baseline at weeks 8-12 and week 20-24 post-treatment compared to baseline (mean Hb values during the 4 weeks prior to the first dose).
For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.
Time frame: Baseline, Week 8-12, Week 20-24
The level of Hb and the change from baseline at each visit throughout the treatment period.
For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Proportion of patients with mean Hb elevation ≥1.0 g/dL from baseline to weeks 8-12 after dosing.
For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.
Time frame: Baseline, Week 8-12
Levels of and changes from baseline in red blood cell count throughout the treatment period
For NTDT cohort, Evaluation of the effect of AND017+BSC on RBC count
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Levels of and changes from baseline in reticulocyte count throughout the treatment period
For NTDT cohort, Evaluation of the effect of AND017+BSC on reticulocyte count
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Levels of and changes from baseline in mean corpuscular volume (MCV) throughout the treatment period
For NTDT cohort, Evaluation of the effect of AND017+BSC on the MCV
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Levels of and changes from baseline in mean corpuscular hemoglobin (MCH) throughout the treatment period
For NTDT cohort, Evaluation of the effect of AND017+BSC on MCH
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Levels of and changes from baseline in mean corpuscular hemoglobin concentration (MCHC) throughout the treatment period
For NTDT cohort, Evaluation of the effect of AND017+BSC on MCHC
Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24
Throughout the treatment period, changes in the levels and relative baseline of transferrin will be assessed.
For NTDT cohort, evaluation of the effect of AND017+BSC on transferrin level
Time frame: From baseline to Week 4, 8, 12, 16, 20, 24
Throughout the treatment period, changes in the levels and relative baseline of transferrin saturation (TSAT) will be assessed.
For NTDT cohort, evaluation of the effect of AND017+BSC on TSAT.
Time frame: From baseline to Week 4, 8, 12, 16, 20, 24
Throughout the treatment period, changes in the levels and relative baseline of ferritin will be assessed.
For NTDT cohort, evaluation of the effect of AND017+BSC on ferritin
Time frame: From baseline to Week 4, 8, 12, 16, 20, 24
Throughout the treatment period, changes in the levels and relative baseline of serum iron level will be assessed.
For NTDT cohort, evaluation of the effect of AND017+BSC on serum iron level
Time frame: From baseline to Week 4, 8, 12, 16, 20, 24
Throughout the treatment period, changes in the levels and relative baseline of total iron binding capacity (TIBC) will be assessed.
For NTDT cohort, evaluation of the effect of AND017+BSC on TIBC
Time frame: From baseline to Week 4, 8, 12, 16, 20, 24
Change in transfusion load (units transfused) at 12-24 weeks post-dose compared to baseline (12 weeks to W0 before first dose).
For TDT cohort, evaluate changes in mean transfusion load by AND017+BSC at 12 to 24 weeks after dosing
Time frame: Baseline, Week 20-24, or End of Treatment if discontinue early
Change in number of transfusions at 12-24 weeks post-dose compared to baseline (12 weeks to W0 before first dose).
For TDT cohort, evaluate changes in mean transfusion load by AND017+BSC at 12 to 24 weeks after dosing
Time frame: Baseline and Week 20-24
Proportion of subjects with ≥33% reduction in transfusion load (transfusion units) relative to baseline (12 weeks prior to first dose to W0) from baseline to any consecutive 12-week period after dosing.
For TDT cohort, proportion of subjects with ≥33% reduction in transfusion load (transfusion units) relative to baseline (12 weeks prior to first dose to W0) from baseline to any consecutive 12-week period after dosing.
Time frame: Baseline, Week 0-12, 2-14, 4-16, 6-18, 8-20, 10-22, and 12-24
Duration (days) of maintenance below this transfusion dose after a 33% reduction in transfusion load from baseline has been achieved.
For TDT cohort, duration (days) of maintenance below this transfusion dose after a 33% reduction in transfusion load from baseline has been achieved.
Time frame: From baseline to Week 24 or End of Treatment if discontinue early
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's planned 31 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AND017
Kind Pharmaceuticals LLC